KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth
KOMZIFTI's commercial launch is strong, with rapid revenue growth, broad market access, and majority share in its target population. Multiple late-stage studies are progressing, with key data readouts and regulatory milestones expected through 2028, while pipeline assets in oncology and diabetes ad…